摘要
纳米医学涉及用于治疗和诊断目的纳米颗粒的应用。在过去的二十年中,越来越多的纳米药物已获得监管部门的批准,并表现出良好的临床应用前景。因此,为了实现生物相容性以及体现其活性,对纳米颗粒的安全性进行评估显得十分重要。然而,由于纳米医学领域包括各种不同材料制成的纳米颗粒,这就并不一定要去强调纳米粒子的安全性。事实上,一些纳米治疗目前正在审批,如阿霉素和白蛋白结合型紫杉醇,尽管它们与比它们的小分子会表现出更小的副作用,其他纳米粒子(如金属和碳基颗粒)往往显示毒性。然而,如果靶点选择可以实现,某些纳米药物的危险性就可以应用于病变组织的消融。本文讨论了分子、细胞、器官和免疫系统的毒性机制,这可以通过纳米粒子的亚群来观测。本文对通过表面修饰和免疫调节剂预处理来提高纳米粒子的安全性的方法就行了讨论。此外,本文对纳米粒子的安全性的重要考察因素进行了概括。对于临床应用,不需要对纳米药物的审批进行更严格的规定。相反,应调整安全评价分析,使其更适于工程纳米粒子。
关键词: 纳米药物,纳米颗粒,纳米安全性,纳米毒性,安全性,毒性。
图形摘要
Current Drug Targets
Title:Safety of Nanoparticles in Medicine
Volume: 16 Issue: 14
Author(s): Joy Wolfram, Motao Zhu, Yong Yang, Jianliang Shen, Emanuela Gentile, Donatella Paolino and Massimo Fresta, Guangjun Nie, Chunying Chen, Haifa Shen, Mauro Ferrari and Yuliang Zhao
Affiliation:
关键词: 纳米药物,纳米颗粒,纳米安全性,纳米毒性,安全性,毒性。
摘要: Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles.
Export Options
About this article
Cite this article as:
Joy Wolfram, Motao Zhu, Yong Yang, Jianliang Shen, Emanuela Gentile, Donatella Paolino and Massimo Fresta, Guangjun Nie, Chunying Chen, Haifa Shen, Mauro Ferrari and Yuliang Zhao , Safety of Nanoparticles in Medicine , Current Drug Targets 2015; 16 (14) . https://dx.doi.org/10.2174/1389450115666140804124808
DOI https://dx.doi.org/10.2174/1389450115666140804124808 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine Use of Dopaminergic Agents in the Treatment-Resistant Depression
Current Psychopharmacology Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis
Current Vascular Pharmacology Pathophysiology of Blood-Brain Barrier in Brain Injury in Cold and Hot Environments: Novel Drug Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Cardiovascular & Hematological Disorders-Drug Targets The Roles of Corticotropin Releasing Factor (CRF) in Responses to Emotional Stress: Is CRF Release a Cause or Result of Fear/Anxiety?
CNS & Neurological Disorders - Drug Targets A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Prevalence, Presentation and Outcome of Secondary Bloodstream Infections among COVID-19 Patients
Infectious Disorders - Drug Targets Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Pharmacology of Adenosine A2A Receptors and Therapeutic Applications
Current Topics in Medicinal Chemistry Recent Advances in the MCRs Synthesis of Chromenes: A Review
Current Organic Chemistry Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers&#
Current Vascular Pharmacology Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Controlled Delivery of Biotechnological Products
Current Pharmaceutical Biotechnology Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety